Lenvatinib mesylate capsules are an anti-tumor drug. Its active ingredient is lenvatinib mesylate, which is a tyrosine kinase receptor inhibitor that can inhibit pathological angiogenesis, tumor growth and progression. It is mainly suitable for patients with unresectable hepatocellular carcinoma who have not received systemic treatment before. The key study of this product excluded patients with hepatocellular carcinoma who could receive local treatment, and there is no available research data for such patients.
Let us work together to protect precious health